The authors found remarkable enhancement of Inoue-Melnick virus (IMV) synthesis b y 5bromodeoxyuridine (BUDR) in human meningioma (MG-1) cells, a virus-producer line of type 1 IMV. Treatment with BUDR resulted in rapid and abundant synthesis of infectious IMV in MG-1 cells. The titer of the cell-ass
5-bromodeoxyuridine enhancement of Inoue-Melnick virus synthesis in human colon carcinoma cell lines
β Scribed by Dr. Y. K. Inoue; Y. Nishibe; T. Kimura
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 359 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
InoueβMelnick virus (IMV) synthesis in naturally infected human colon carcinoma cell lines can be enhanced by 5βbromodeoxyurdine (BUDR). The optimal conditions for BUDR enhancement differed between two cell lines, SWβ480 and DLDβ1, SWβ480 cells produced 100 times more infectious IMV than DLDβ1 cells by BUDR treatment. A clonal difference in IMV synthesis in SWβ480 cells was also observed. The highest titer of virus was found in the culture fluid of clone H (SWβ480/H) cells treated with BUDR, and a herpesβlike virus was detected by negativestaining electron microscopy of concentrates of the culture fluid. One nonproducer clone (SWβ480/B) was also activated to produce virus when treated with BUDR.
π SIMILAR VOLUMES
Inoue-Melnick virus (IMV) was isolated from five of six human colorectal carcinoma cell lines, whereas the virus was not isolated from three normal colon-derived cell lines, three pancreas carcinoma cell lines, two bladder carcinoma cell lines, one kidney adenocarcinoma cell line, and one cervical c
We investigated continuous production of Inoue-Melnick virus (IMV) in the MG-1 cell line, established from human meningioma. The infectious virus, identified as a type 1 virus, was mostly recovered extracellularly. Assay of MG-1 cells as infective centers indicated that most of the cells were capabl
## Abstract The antibody prevalence rate of 3 types of IMV in 24 sera of Japanese patients with colorectal adenocarcinoma (mean age 60.8 years) was 83.3% (20/24). Of 20 positive sera, 19 contained type 1 antibody and one contained type 2. In contrast, the seropositivity of IMV in 21 sera of matched